Brief: Cabaletta Bio Reports Clinical Data From Third Dose Cohort In DesCAARTes Trial In Patients With mPV
01/11/2021 11:07
Nov 1 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO REPORTS CLINICAL DATA FROM THE THIRD DOSE
COHORT
IN DESCAARTES™ TRIAL IN PATIENTS WITH MPV
* CABALETTA BIO INC - TOP-LINE BIOLOGIC ACTIVITY DATA FOR
FIRST
TWO LOW DOSE COHORTS ANTICIPATED TO BE ANNOUNCED IN 4Q21
* CABALETTA BIO INC - DOSING INITIATED IN FOURTH PATIENT
COHORT AT
A DOSE OF 2.5 BILLION DSG3-CAART CELLS WITH 28-DAY SAFETY DATA
ANTICIPATED IN 1Q22
Source text for Eikon: ID:nGNX7J3Dn7
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity